All Things Biosimilar

All Things Biosimilar

Stay on the pulse of the U.S. biosimilars industry with All Things Biosimilar. Hosted by Andrew Bourgoin, founder of Bourgoin Insights Group, this podcast is your source for timely insights into the dynamic biosimilar market. Each episode unpacks the latest developments, including in-depth analysis of the U.S. retina market, the competitive dynamics for ustekinumab and aflibercept biosimilars, and what to watch for in quarterly earnings. If you need to understand the forces driving the market today, this is the podcast for you. Subscribe to stay informed.

에피소드

  1. 2025. 11. 25.

    All Things Biosimilar - Episode 3

    Welcome to All Things Biosimilar Podcast Join Andrew Bourgoin, founder of Bourgoin Insights Group, as he introduces the All Things Biosimilar Podcast, an insightful series dedicated to the US biosimilars market. With over 15 years of industry experience, Andrew discusses various topics related to the market. Subscribe now to stay informed about the evolving U.S. biosimilars landscape. In Episode Three of the All Things Biosimilar Podcast:  We hand out stuffing and peas across products, manufacturers, markets and others- and share our 2c on impact FDA guidance updates may have on the competitive landscape. Happy Thanksgiving! 00:00 Introduction and Thanksgiving Greetings 01:40 2025 Stuffing and Peas: Products 04:22 2025 Stuffing and Peas: Manufacturers 06:32 2025 Stuffing and Peas: Markets 10:36 2025 Stuffing and Peas: Other Category 13:36 FDA Regulations and Biosimilar Market Impact 28:47 Final Words and Gratitude Connect with us! Website: www.Bourgoininsightsgroup.com LinkedIn: https://www.linkedin.com/company/bourgoin-insights-group Disclaimer: Bourgoin Insights Group, LLC publishes market intelligence reports on various Biosimilars, Biologics, and the U.S. Biosimilar industry. All reports, both published publicly and those provided pursuant to part of a subscription to All Things Biosimilar are subject to the following disclaimer. A subscription to All Things Biosimilar automatically indicates acceptance of the disclaimer. We, at Bourgoin Insights Group, LLC, gather information from various sources such paid databases, published reports, FDA databases, annual reports, surveys and media releases. This public information is collated in good faith in preparation of analysis and used on an as is and as available basis by us. Connect with us! Website: www.Bourgoininsightsgroup.com LinkedIn: https://www.linkedin.com/company/bourgoin-insights-group Music: Bang Boom - Captain Joz Production: Maine Frame Disclaimer: Bourgoin Insights Group, LLC publishes market intelligence reports on various Biosimilars, Biologics, and the U.S. Biosimilar industry. All reports, both published publicly and those provided pursuant to part of a subscription to All Things Biosimilar are subject to the following disclaimer. A subscription to All Things Biosimilar automatically indicates acceptance of the disclaimer. We, at Bourgoin Insights Group, LLC, gather information from various sources such paid databases, published reports, FDA databases, annual reports, surveys and media releases. This public information is collated in good faith in preparation of analysis and used on an as is and as available basis by us.

  2. 2025. 10. 15.

    All Things Biosimilar - Episode 1

    Welcome to All Things Biosimilar Podcast Join Andrew Bourgoin, founder of Bourgoin Insights Group, as he introduces the All Things Biosimilar Podcast, an insightful series dedicated to the US biosimilars market. With over 15 years of industry experience, Andrew discusses various topics related to the market. Subscribe now to stay informed about the evolving U.S. biosimilars landscape. In Episode One of the All Things Biosimilar Podcast: U.S. Ustekinumab Biosimilars Market YTD U.S. Biosimilars Market Survey: Who Do You Think Will Be Leading the Next Decade? Zarxio Turns 10 Chapters:  00:00 Introduction to the Episode One 01:07 Big Topic 1: US Stelara Biosimilars Market 08:11 Big Topic 2:  Survey Results: Top Biosimilar Companies 11:05 Big Topic 3: Zarxio Turns 10 Connect with us! Website: www.Bourgoininsightsgroup.com LinkedIn: https://www.linkedin.com/company/bourgoin-insights-group Music: Bang Boom - Captain Joz Production: Maine Frame Disclaimer: Bourgoin Insights Group, LLC publishes market intelligence reports on various Biosimilars, Biologics, and the U.S. Biosimilar industry. All reports, both published publicly and those provided pursuant to part of a subscription to All Things Biosimilar are subject to the following disclaimer. A subscription to All Things Biosimilar automatically indicates acceptance of the disclaimer. We, at Bourgoin Insights Group, LLC, gather information from various sources such paid databases, published reports, FDA databases, annual reports, surveys and media releases. This public information is collated in good faith in preparation of analysis and used on an as is and as available basis by us.

  3. 2025. 10. 15.

    All Things Biosimilar - Episode 2

    Welcome to All Things Biosimilar Podcast Join Andrew Bourgoin, founder of Bourgoin Insights Group, as he introduces the All Things Biosimilar Podcast, an insightful series dedicated to the US biosimilars market. With over 15 years of industry experience, Andrew discusses various topics related to the market. Subscribe now to stay informed about the evolving U.S. biosimilars landscape. In Episode Two of the All Things Biosimilar Podcast:  Biosimilars and Total Addressable Market Analysis, U.S. Retina Market Dynamics, Q3 Earnings Season Preview  00:00 Introduction and Episode Overview  01:47 Feedback from Episode One  02:36 Topic 1: Understanding TAM in Biosimilars  05:51 Case Study: Coherus and TAM Analysis  07:21 Detailed Market Analysis: Remicade, Herceptin, and Lucentis  18:08 Portfolio Analysis and Future Projections  24:04 Applying TAM Scenarios to Companies  28:03 Analyzing Biosimilar Market Performance  29:31 Exploring the US Retina Market  30:54 Competitive Landscape for Aflibercept Biosimilars  35:51 Upcoming Biosimilar Market Activities  40:09 Earnings Season Preview: Key Questions and Topics  43:15 Company-Specific Earnings Insights  52:55 Conclusion and Upcoming Episodes Connect with us! Website: www.Bourgoininsightsgroup.com LinkedIn: https://www.linkedin.com/company/bourgoin-insights-group Music: Bang Boom - Captain Joz Production: Maine Frame Disclaimer: Bourgoin Insights Group, LLC publishes market intelligence reports on various Biosimilars, Biologics, and the U.S. Biosimilar industry. All reports, both published publicly and those provided pursuant to part of a subscription to All Things Biosimilar are subject to the following disclaimer. A subscription to All Things Biosimilar automatically indicates acceptance of the disclaimer. We, at Bourgoin Insights Group, LLC, gather information from various sources such paid databases, published reports, FDA databases, annual reports, surveys and media releases. This public information is collated in good faith in preparation of analysis and used on an as is and as available basis by us.

  4. 2025. 10. 15.

    All Things Biosmilar - Introduction

    Welcome to All Things Biosimilar Podcast Join Andrew Bourgoin, founder of Bourgoin Insights Group, as he introduces the All Things Biosimilar Podcast, an insightful series dedicated to the US biosimilars market. With over 15 years of industry experience, Andrew discusses the podcast's goal to deliver comprehensive analysis, timely market insights, and monitoring services. Learn about the 351K report and how it benefits both seasoned professionals and newcomers. Stay tuned for monthly episodes featuring key topics, special guests, and much more. Subscribe now to stay informed about the evolving biosimilars landscape. 00:00 Introduction to All Things Biosimilar Podcast 01:01 About Bourgoin Insights Group 01:38 The 351 K Report 01:57 Positive Feedback and New Ideas 02:41 Launching the Podcast 03:08 Future Plans and Engagement 04:14 Stay Connected Connect with us! Website: www.Bourgoininsightsgroup.com LinkedIn: https://www.linkedin.com/company/bourgoin-insights-group Music: Bang Boom - Captain Joz Production: Maine Frame Disclaimer: Bourgoin Insights Group, LLC publishes market intelligence reports on various Biosimilars, Biologics, and the U.S. Biosimilar industry. All reports, both published publicly and those provided pursuant to part of a subscription to All Things Biosimilar are subject to the following disclaimer. A subscription to All Things Biosimilar automatically indicates acceptance of the disclaimer. We, at Bourgoin Insights Group, LLC, gather information from various sources such paid databases, published reports, FDA databases, annual reports, surveys and media releases. This public information is collated in good faith in preparation of analysis and used on an as is and as available basis by us.

  • 4개의 에피소드

소개

Stay on the pulse of the U.S. biosimilars industry with All Things Biosimilar. Hosted by Andrew Bourgoin, founder of Bourgoin Insights Group, this podcast is your source for timely insights into the dynamic biosimilar market. Each episode unpacks the latest developments, including in-depth analysis of the U.S. retina market, the competitive dynamics for ustekinumab and aflibercept biosimilars, and what to watch for in quarterly earnings. If you need to understand the forces driving the market today, this is the podcast for you. Subscribe to stay informed.

정보

  • 제작진
    All Things Biosimilar
  • 방송 연도
    2025년
  • 에피소드
    4
  • 등급
    무삭제판
  • 저작권
    © 2025 All Things Biosimilar